ConductScience.org, home

Paper30899360

Therapeutic targeting of immune checkpoints with small molecule inhibitors.

Smith WM and 9 others. Am J Transl Res, 2019. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic targeting of immune checkpoints with small molecule inhibitors. Papers, record 30899360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30899360

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic targeting of immune checkpoints with small molecule inhibitors.
PubMed
Journal
Am J Transl Res
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
0.82
iCite
Revised in PubMed
2020-10-01
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Smith WMWade M
2Purvis IJIan J
3Bomstad CNColin N
4Labak CMCollin M
5Velpula KKKiran K
6Tsung AJAndrew J
7Regan JNJenna N
8Venkataraman SSujatha
9Vibhakar RRajeev
10Asuthkar SSwapna

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References99

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110365964Structure and ligand of a histone acetyltransferase bromodomain.Nature1999https://conductscience.org/library/papers/10365964PubMed
210485649Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity1999https://conductscience.org/library/papers/10485649PubMed
310601994Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses.Eur J Immunol1999https://conductscience.org/library/papers/10601994PubMed
410880530Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3.J Exp Med2000https://conductscience.org/library/papers/10880530PubMed
511419179The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma.Cancer Immunol Immunother2001https://conductscience.org/library/papers/11419179PubMed
611584304The renaissance of GSK3.Nat Rev Mol Cell Biol2001https://conductscience.org/library/papers/11584304PubMed
711741888Small molecule ligands define a binding site on the immune regulatory protein B7.1.J Biol Chem2002https://conductscience.org/library/papers/11741888PubMed
812091876Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med2002https://conductscience.org/library/papers/12091876PubMed
912646627Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway.J Immunol2003https://conductscience.org/library/papers/12646627PubMed
1012788368Structure-activity studies of a series of dipyrazolo[3,4-b:3',4'-d]pyridin-3-ones binding to the immune regulatory protein B7.1.Bioorg Med Chem2003https://conductscience.org/library/papers/12788368PubMed
111396582Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J1992https://conductscience.org/library/papers/1396582PubMed
1215485628Role of LAG-3 in regulatory T cells.Immunity2004https://conductscience.org/library/papers/15485628PubMed
1315610849High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy.Chem Biol2004https://conductscience.org/library/papers/15610849PubMed
1415971272Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.Eur J Immunol2005https://conductscience.org/library/papers/15971272PubMed
1516307490Histone deacetylase inhibitors: discovery and development as anticancer agents.Expert Opin Investig Drugs2005https://conductscience.org/library/papers/16307490PubMed
1616924108OX40 ligand shuts down IL-10-producing regulatory T cells.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16924108PubMed
1716931720Reversal of the TCR stop signal by CTLA-4.Science2006https://conductscience.org/library/papers/16931720PubMed
1817560335Genes that distinguish physiological and pathological angiogenesis.Cancer Cell2007https://conductscience.org/library/papers/17560335PubMed
1917575071OX40 costimulation turns off Foxp3+ Tregs.Blood2007https://conductscience.org/library/papers/17575071PubMed
2017785860A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.J Immunol2007https://conductscience.org/library/papers/17785860PubMed

See all 99 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
41294857Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives.Cells2025https://conductscience.org/library/papers/41294857PubMed
40624659One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.Cancer Cell Int2025https://conductscience.org/library/papers/40624659PubMed
39161771Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance.Front Immunol2024https://conductscience.org/library/papers/39161771PubMed
39026528Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival.Clin Transl Immunology2024https://conductscience.org/library/papers/39026528PubMed
38956700Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer.Eur J Med Res2024https://conductscience.org/library/papers/38956700PubMed
38833067A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.Invest New Drugs2024https://conductscience.org/library/papers/38833067PubMed
38321096Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules.Sci Rep2024https://conductscience.org/library/papers/38321096PubMed
38248769Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.J Pers Med2024https://conductscience.org/library/papers/38248769PubMed
37999131Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).Curr Oncol2023https://conductscience.org/library/papers/37999131PubMed
36982802Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.Int J Mol Sci2023https://conductscience.org/library/papers/36982802PubMed
36551637Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade.Cancers (Basel)2022https://conductscience.org/library/papers/36551637PubMed
36413426Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.Mol Pharm2022https://conductscience.org/library/papers/36413426PubMed
35757459Dual Effect of the Extract from the Fungus Coriolus versicolor on Lipopolysaccharide-Induced Cytokine Production in RAW 264.7 Macrophages Depending on the Lipopolysaccharide Concentration.J Inflamm Res2022https://conductscience.org/library/papers/35757459PubMed
34996924In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.Sci Rep2022https://conductscience.org/library/papers/34996924PubMed
34858943Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts.Front Chem2021https://conductscience.org/library/papers/34858943PubMed
34452059Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives.Vaccines (Basel)2021https://conductscience.org/library/papers/34452059PubMed
33777676Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.Acta Pharm Sin B2021https://conductscience.org/library/papers/33777676PubMed
32988398Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.Genome Med2020https://conductscience.org/library/papers/32988398PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30899360

GET https://conductscience.org/api/papers/v1/30899360/references?page=2